Search Results - "Nowakowski, Grzegorz"

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Nedved, Adrienne, Maddocks, Kami, Nowakowski, Grzegorz S

“…Abstract Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of…”
Get full text

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma by Leonard, John P, Trneny, Marek, Izutsu, Koji, Fowler, Nathan H, Hong, Xiaonan, Zhu, Jun, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana, Nowakowski, Grzegorz S, Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian W, Moreira, Claudia, Cabeçadas, José, Liu, David, Kalambakas, Stacey, Fustier, Pierre, Wu, Chengqing, Gribben, John G

“…Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly…”
Get full text

Diffuse large B-cell lymphoma: new targets and novel therapies by Cheson, Bruce D., Nowakowski, Grzegorz, Salles, Gilles

“…Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies…”
Get full text

DLBCL: Who is high risk and how should treatment be optimized? by Dabrowska-Iwanicka, Anna P, Nowakowski, Grzegorz S

“…Diffuse large B-cell lymphoma (DLBCL) not otherwise specified is the most common subtype of large B-cell lymphoma group, with differences in prognosis,…”
Get full text

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma by Nowakowski, Grzegorz S, Chiappella, Annalisa, Gascoyne, Randy D, Scott, David W, Zhang, Qingyuan, Jurczak, Wojciech, Özcan, Muhit, Hong, Xiaonan, Zhu, Jun, Jin, Jie, Belada, David, Bergua, Juan Miguel, Piazza, Francesco, Mócikova, Heidi, Molinari, Anna Lia, Yoon, Dok Hyun, Cavallo, Federica, Tani, Monica, Yamamoto, Kazuhito, Izutsu, Koji, Kato, Koji, Czuczman, Myron, Hersey, Sarah, Kilcoyne, Adrian, Russo, Jacqueline, Hudak, Krista, Zhang, Jingshan, Wade, Steve, Witzig, Thomas E, Vitolo, Umberto

“…Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab…”
Get full text

Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL by Munoz, Javier, Deshpande, Anagha, Rimsza, Lisa, Nowakowski, Grzegorz S., Kurzrock, Razelle

“…•Modifying R-CHOP for DLBCL has been challenging and not reached goal efficacy.•Polatuzumab vedotin led to a breakthrough but did not achieve a universal cure…”
Get full text

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis by Wang, Yucai, Zhou, Shouhao, Yang, Fang, Qi, Xinyue, Wang, Xin, Guan, Xiaoxiang, Shen, Chan, Duma, Narjust, Vera Aguilera, Jesus, Chintakuntlawar, Ashish, Price, Katharine A, Molina, Julian R, Pagliaro, Lance C, Halfdanarson, Thorvardur R, Grothey, Axel, Markovic, Svetomir N, Nowakowski, Grzegorz S, Ansell, Stephen M, Wang, Michael L

“…Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the…”
Get more information

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease by Goyal, Gaurav, Ravindran, Aishwarya, Young, Jason R, Shah, Mithun V, Bennani, N Nora, Patnaik, Mrinal M, Nowakowski, Grzegorz S, Thanarajasingam, Gita, Habermann, Thomas M, Vassallo, Robert, Sher, Taimur, Parikh, Sameer A, Rech, Karen L, Go, Ronald S

“…Rosai-Dorfman disease is a rare subtype of non-Langerhans cell histiocytosis. With the last major report published in 1990, there is a paucity of contemporary…”
Get full text

Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma by Nowakowski, Grzegorz S

Get full text

Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment by Bock, Allison M., Nowakowski, Grzegorz S., Wang, Yucai

“…Opinion Statement While there have been numerous advances in the field of non-Hodgkin lymphoma (NHL) over the last decade, relapsed and/or refractory (R/R) NHL…”
Get full text

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 by Nowakowski, Grzegorz S, Hong, Fangxin, Scott, David W, Macon, William R, King, Rebecca L, Habermann, Thomas M, Wagner-Johnston, Nina, Casulo, Carla, Wade, James L, Nagargoje, Gauri G, Reynolds, C M, Cohen, Jonathon B, Khan, Nadia, Amengual, Jennifer E, Richards, Kristy L, Little, R F, Leonard, John P, Friedberg, Jonathan W, Kostakoglu, Lale, Kahl, Brad S, Witzig, Thomas E

“…Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell…”
Get full text

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology by Scott, David W., King, Rebecca L., Staiger, Annette M., Ben-Neriah, Susana, Jiang, Aixiang, Horn, Heike, Mottok, Anja, Farinha, Pedro, Slack, Graham W., Ennishi, Daisuke, Schmitz, Norbert, Pfreundschuh, Michael, Nowakowski, Grzegorz S., Kahl, Brad S., Connors, Joseph M., Gascoyne, Randy D., Ott, German, Macon, William R., Rosenwald, Andreas

“…High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) is a newly defined entity in the latest World Health Organization…”
Get full text

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL by Ding, Wei, LaPlant, Betsy R., Call, Timothy G., Parikh, Sameer A., Leis, Jose F., He, Rong, Shanafelt, Tait D., Sinha, Sutapa, Le-Rademacher, Jennifer, Feldman, Andrew L., Habermann, Thomas M., Witzig, Thomas E., Wiseman, Gregory A., Lin, Yi, Asmus, Erik, Nowakowski, Grzegorz S., Conte, Michael J., Bowen, Deborah A., Aitken, Casey N., Van Dyke, Daniel L., Greipp, Patricia T., Liu, Xin, Wu, Xiaosheng, Zhang, Henan, Secreto, Charla R., Tian, Shulan, Braggio, Esteban, Wellik, Linda E., Micallef, Ivana, Viswanatha, David S., Yan, Huihuang, Chanan-Khan, Asher A., Kay, Neil E., Dong, Haidong, Ansell, Stephen M.

“…Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short survival of about 4 months…”
Get full text

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials by Maurer, Matthew J, Ghesquières, Hervé, Link, Brian K, Jais, Jean-Philippe, Habermann, Thomas M, Thompson, Carrie A, Haioun, Corinne, Allmer, Cristine, Johnston, Patrick B, Delarue, Richard, Micallef, Ivana N, Peyrade, Frederic, Inwards, David J, Ketterer, Nicolas, Farooq, Umar, Fitoussi, Olivier, Macon, William R, Molina, Thierry J, Syrbu, Sergei, Feldman, Andrew L, Slager, Susan L, Weiner, George J, Ansell, Stephen M, Cerhan, James R, Salles, Gilles A, Witzig, Thomas E, Tilly, Hervé, Nowakowski, Grzegorz S

“…Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is…”
Get full text

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement by Oyer, Randall A, Hurley, Patricia, Boehmer, Leigh, Bruinooge, Suanna Steeby, Levit, Kathryn, Barrett, Nadine, Benson, Al, Bernick, Lea Ann, Byatt, Leslie, Charlot, Marjory, Crews, Jennie, DeLeon, Kyle, Fashoyin-Aje, Lola, Garrett-Mayer, Elizabeth, Gralow, Julie R, Green, Sybil, Guerra, Carmen E, Hamroun, Leila, Hardy, Claudia M, Hempstead, Bridgette, Jeames, Sanford, Mann, Mel, Matin, Khalid, McCaskill-Stevens, Worta, Merrill, Janette, Nowakowski, Grzegorz S, Patel, Manali I, Pressman, Alice, Ramirez, Amelie G, Segura, Juanita, Segarra-Vasquez, Barbara, Hanley Williams, Jen, Williams, Jr, James E, Winkfield, Karen M, Yang, Eddy S, Zwicker, Victoria, Pierce, Lori J

“…A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical…”
Get full text

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource by LINK, Brian K, MAURER, Matthew J, COLGAN, Joseph P, WITZIG, Thomas E, HABERMANN, Thomas M, CERHAN, James R, NOWAKOWSKI, Grzegorz S, ANSELL, Stephen M, MACON, William R, SYRBU, Sergei I, SLAGER, Susan L, THOMPSON, Carrie A, INWARDS, David J, JOHNSTON, Patrick B

“…Purpose This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series…”
Get full text

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study by Nowakowski, Grzegorz S, LaPlant, Betsy, Macon, William R, Reeder, Craig B, Foran, James M, Nelson, Garth D, Thompson, Carrie A, Rivera, Candido E, Inwards, David J, Micallef, Ivana N, Johnston, Patrick B, Porrata, Luis F, Ansell, Stephen M, Gascoyne, Randy D, Habermann, Thomas M, Witzig, Thomas E

“…Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined…”
Get full text

Evolution: IMiDs to PPMs, revolution in DLBCL? by Nowakowski, Grzegorz S.

“…In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of diffuse large B-cell lymphoma…”
Get full text

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma by Thompson, Carrie A, Ghesquieres, Herve, Maurer, Matthew J, Cerhan, James R, Biron, Pierre, Ansell, Stephen M, Chassagne-Clément, Catherine, Inwards, David J, Gargi, Thérèse, Johnston, Patrick B, Nicolas-Virelizier, Emmanuelle, Macon, William R, Peix, Marie, Micallef, Ivana N, Sebban, Catherine, Nowakowski, Grzegorz S, Porrata, Luis F, Weiner, George J, Witzig, Thomas E, Habermann, Thomas M, Link, Brian K

“…We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL)…”
Get full text

CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under by Atallah-Yunes, Suheil Albert, Rees, Matthew J, Witzig, Thomas E, Habermann, Thomas M, Munoz, Javier, Iqbal, Madiha, McPhail, Ellen D, Nowakowski, Grzegorz S

“…Intensified chemoimmunotherapy regimens are often used in young patients with double hit and triple hit lymphoma (DHL/THL) despite no survival benefit compared…”
Get full text